Treatment and prevention of ocular neurodegenerative disorder
AssigneeThe Jackson Laboratory
InventorsSimon W. M. John, Peter Alexander Williams
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a pharmaceutical composition containing nicotinamide (NAM) and/or pyruvate as a neuroprotective medicament or gene therapy in the treatment of neurodegenerative disorders, in particular axon degeneration of neuronal tissue in ocular-related neurodegeneration diseases including glaucoma.
Claims19
A method of reducing axonal degeneration of a retinal ganglion cell and treating glaucoma in a subject in need thereof, comprising the step of orally administering to the subject a therapeutically effective amount of nicotinamide (NAM) and pyruvate wherein the subject is a mammal and administered between 1 and 5 g/day of NAM and between 1 and 5 g/day of pyruvate, wherein axonal degeneration in a retinal ganglion cell is reduced.
A method of preventing glaucoma in a subject in need thereof, comprising the step of orally administering to the subject a pharmaceutical composition containing a therapeutically effective amount of nicotinamide (NAM) and pyruvate to reduce axonal degeneration in a retinal ganglion cell and prevent glaucoma, wherein the subject is a mammal and is administered between 1 and 5 g/day of NAM and between 1 and 5 g/day of pyruvate.
A method of improving visual function in a subject in need thereof, comprising the step of orally administering to the subject a pharmaceutical composition containing a therapeutically effective amount of nicotinamide (NAM) and pyruvate to reduce axonal degeneration in a retinal ganglion cell and improve visual function, wherein the subject is a mammal and is administered between 1 and 5 g/day of NAM and 10 between 1 and 5 g/day of pyruvate.
Dependencies are inferred from the claim text.